PMC® Announces Sponsorship of PMLiVE Pharmaceutical Market Excellence Awards 30 Sep 2020
PMC® is delighted to announce its sponsorship of the Excellence in Rare Diseases and Orphan Drugs category at the annual Pharmaceutical Market Excellence Awards (PMEA) on 25th November 2020.
The PMEA provides a respected forum for celebrating excellence in improving patient outcomes. Each year, an independent panel of seasoned pharmaceutical experts recognises exceptional achievements from around the industry in categories ranging from brand management to patient-centricity. We are excited to be involved in this year’s virtual event as a category sponsor to help showcase the outstanding work of our colleagues in bringing vital medicines for rare diseases to patients.
Speaking about the sponsorship, Dr Malcolm Barratt-Johnson, Managing Director of PMC® said, “One in fifteen people around the world is affected by a rare disease. Delivering medicines to these patients, many of whom are in great need, is a critical endeavour. We are proud to be part of the effort through our work supporting essential medical and regulatory affairs activities for several clients working in the orphan diseases space. “
PMC® supports pharmaceutical and biotechnology companies from start-up through to product launch and beyond with cost-effective and flexible virtual medical affairs solutions. We look forward to presenting the award to the winner of the Excellence in Rare Diseases and Orphan Drugs category at PMEA on 25th November and hope to see you there. If you would like to discuss how we can help you, please get in touch at firstname.lastname@example.org.
To learn more about PMEA click here: http://www.pmlive.com/awards/pmea